证券代码：603207 证券简称：小方制药 上海小方制药股份有限公司 2026 年第一次临时股东会 会 议 资 料 2026 年 3 月 | | | 2026 年第一次临时股东会会议须知 为了维护全体股东的合法权益，确保上海小方制药股份有限公司（以下简称 "公司"）股东会的正常秩序和议事效率，保证会议的顺利进行，根据《中华人民 共和国公司法》《中华人民共和国证券法》《上市公司股东会规则》以及《上海小 方制药股份有限公司章程》（以下简称"《公司章程》"）《上海小方制药股份有限 公司股东会议事规则》等相关规定，特制定本须知： 一、 为确认出席会议的股东或其代理人或其他出席者的出席资格，会议 工作人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 八、 出席股东会的股东及股东代理人，应当对提交表决的议案发表如下 意见之一：同意、反对或弃权。未填、错填、字迹无法辨认的表决票、未投的表 决票均视投票人放弃表决权利，其所持股份的表决结果计为"弃权"。本次公司仅 选举 1 名董事，因此本次董事选举实行非累积投票制，与会股东所持每一股份享 有一票表决权。请与会股东按表决票要求填写表决票。 九、 本次股东会采取现 ...

Core Viewpoint - The company plans to utilize part of its temporarily idle raised funds for cash management, ensuring that it does not affect the normal investment plan and guarantees fund safety [2]. Group 1: Cash Management Plan - The company intends to use up to RMB 200,000,000 (including principal) of idle raised funds for cash management, focusing on high-security, good liquidity, and capital preservation bank deposit products [2]. - The cash management products may include but are not limited to agreement deposits, time deposits, and large-denomination certificates of deposit, with a maximum term of 12 months [2]. - This cash management plan does not require submission for shareholder meeting approval [2]. Group 2: Current Status of Cash Management - As of the announcement date, the company has a remaining balance of RMB 54,000,000 from the temporarily idle raised funds used for cash management [2]. - The highest daily balance and usage period of the idle raised funds for cash management have not exceeded the authorization range set by the company's board of directors [2].

证券代码：603207 证券简称：小方制药 公告编号：2026-002 上海小方制药股份有限公司 关于使用部分暂时闲置募集资金进行现金管理赎回 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海小方制药股份有限公司（以下简称"公司"）于2025年10月24日召开 了第二届董事会第六次会议、第二届监事会第六次会议，审议通过了《关于上 海小方制药股份有限公司使用部分暂时闲置募集资金进行现金管理的议案》， 公司在保证不影响募集资金投资计划正常进行以及确保资金安全的前提下，拟 使用不超过人民币200,000,000元（含本数）的闲置募集资金进行现金管理，用 于购买期限最长不超过12个月的安全性高、流动性好、满足保本要求的银行存 款类产品（包括但不限于协定性存款、定期存款、大额存单等）。本事项无需 提交公司股东会审议。保荐机构国信证券股份有限公司对本事项出具了无异议 的核查意见。具体内容详见公司在上海证券交易所网站（www.sse.com.cn）及 指定信息披露媒体披露的《关于上海小方制药股份有限公司使用部分暂时闲置 募集资金 ...

Group 1 - The core viewpoint of the news is that Xiaofang Pharmaceutical has shown a slight decline in stock price while maintaining a relatively low financing balance compared to its market value, indicating potential investment opportunities [1] - As of February 9, Xiaofang Pharmaceutical's financing balance is 60.80 million yuan, which accounts for 3.69% of its circulating market value, and is below the 10th percentile level over the past year, suggesting a low financing position [1] - The company reported a total revenue of 397 million yuan for the period from January to September 2025, reflecting a year-on-year growth of 8.17%, while the net profit attributable to shareholders increased by 5.09% to 170 million yuan [2] Group 2 - Xiaofang Pharmaceutical has distributed a total of 353 million yuan in dividends since its A-share listing, indicating a commitment to returning value to shareholders [3] - As of September 30, 2025, the number of shareholders has increased to 14,300, with an average of 3,807 circulating shares per person, showing a slight increase in shareholder engagement [2] - Notably, new institutional investors have entered the top ten circulating shareholders list, with GF Multi-Dimensional Emerging Stock holding 753,100 shares, while some previous major shareholders have exited [3]

Core Viewpoint - The announcement details the results of the 2025 restricted stock incentive plan of Shanghai Xiaofang Pharmaceutical Co., Ltd., including the number of shares granted and the conditions surrounding the stock awards [2][3]. Group 1: Restricted Stock Grant Details - The registration date for the reserved grant of restricted stock is February 2, 2026 [2]. - A total of 260,033 shares were granted to 23 eligible participants after 7 participants voluntarily forfeited 59,967 shares [3][5]. - The grant price for the restricted stock is set at 12.77 yuan per share [5]. Group 2: Incentive Plan Conditions - The effective period of the restricted stock is up to 36 months from the completion of the registration [6]. - The lock-up period for the granted restricted stock is 12 to 24 months, during which the stock cannot be transferred or used as collateral [7]. Group 3: Financial Aspects - The total funds received from the 23 participants amount to 3,320,621.41 yuan, with 260,033 yuan allocated to share capital and the remainder to capital reserves [9]. - The company plans to use the funds raised from this incentive plan to supplement its working capital [12]. Group 4: Impact on Shareholding Structure - The completion of the restricted stock registration will not lead to any changes in the company's controlling shareholder or actual controller [11].

证券代码：603207 证券简称：小方制药 公告编号：2026-001 上海小方制药股份有限公司 关于 2025 年限制性股票激励计划预留授予结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●限制性股票预留授予登记日：2026 年 2 月 2 日 ●限制性股票预留授予登记数量：260033 股 根据《上市公司股权激励管理办法》的规定，按照上海证券交易所、中国证 券登记结算有限责任公司上海分公司的有关要求，上海小方制药股份有限公司 （以下简称"公司"）于近日在中国证券登记结算有限责任公司上海分公司办理完 成了公司 2025 年限制性股票激励计划（以下简称"本激励计划"）的预留授予登 记工作，现将相关事项公告如下： 一、限制性股票授予情况 公司于 2025 年 12 月 19 日召开第二届董事会第八次会议，审议通过了《关 于向公司 2025 年限制性股票激励计划激励对象授予预留部分限制性股票的议 案》，公司董事会认为本激励计划规定的限制性股票预留授予条件已经成就，同 意确定以 2025 年 12 月 19 ...

Group 1 - The core viewpoint of the news is that Xiaofang Pharmaceutical has shown a slight decline in stock price and has low financing balance, indicating a potential investment opportunity due to its low valuation [1] - As of December 30, Xiaofang Pharmaceutical's financing balance is 77.59 million, accounting for 4.97% of its market capitalization, which is below the 30th percentile level over the past year, indicating a low financing level [1] - The company reported a revenue of 397 million for the period from January to September 2025, representing a year-on-year growth of 8.17%, and a net profit of 170 million, with a growth of 5.09% [2] Group 2 - Xiaofang Pharmaceutical has distributed a total of 353 million in dividends since its A-share listing [3] - As of September 30, 2025, the number of shareholders has increased to 14,300, with an average of 3,807 circulating shares per person, which has decreased by 0.32% compared to the previous period [2] - Notably, Guangfa Multi-Strategy Emerging Stock is now among the top ten shareholders, holding 753,100 shares as a new shareholder, while several other funds have exited the top ten list [3]

Group 1 - The core point of the article is that Xiaofang Pharmaceutical (603207) has disclosed the number of shareholders as of December 10, 2025, which is 14,287 households [1]

Core Viewpoint - The company emphasizes its commitment to enhancing intrinsic value and achieving long-term shareholder returns while closely monitoring capital market performance [1] Group 1 - The management is actively researching and promoting relevant plans when feasible, considering market conditions, funding arrangements, business development needs, and compliance requirements [1] - The company is dedicated to strictly adhering to legal regulations in decision-making processes and information disclosure obligations [1]

Group 1 - The company announced the approval of adjustments to its 2025 restricted stock incentive plan during the eighth meeting of its second board of directors [2] - The company also approved the proposal to grant reserved restricted stocks to the incentive targets under the 2025 restricted stock incentive plan [2]